Novo Nordisk A/S (CPH:NOVO.B)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 1.38T |
| Revenue (ttm) | 315.60B |
| Net Income (ttm) | 103.77B |
| Shares Out | 4.44B |
| EPS (ttm) | 23.33 |
| PE Ratio | 13.27 |
| Forward PE | 12.54 |
| Dividend | 11.65 (3.81%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 5,369,194 |
| Average Volume | 7,395,845 |
| Open | 309.00 |
| Previous Close | 305.80 |
| Day's Range | 307.80 - 315.10 |
| 52-Week Range | 266.90 - 798.10 |
| Beta | 0.35 |
| RSI | 47.02 |
| Earnings Date | Feb 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial StatementsNews
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?
Novo Nordisk's semaglutide failed in pivotal studies as a treatment for Alzheimer's disease. This isn't a significant obstacle to the drugmaker's prospects, despite what the market reaction suggests.
Pre-Market Most Active for Dec 5, 2025 : NVO, NIO, QBTS, SMR, BBAI, IONQ
The NASDAQ 100 Pre-Market Indicator is down -.41 to 25,581.29. The total Pre-Market volume is currently 91,889,714 shares traded.The following are the most active stocks for the pre-market session: No...
India's Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact
Indian health-tech startup Healthify is in talks to partner with more weight-loss drugmakers to offer health, nutrition and lifestyle coaching, after signing a deal with Novo Nordisk's India unit, its...
India Court Allows Dr. Reddy’s to Export Generics of Novo Nordisk’s Semaglutide Drug
An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s obesity and diabetes drugs, ahead of global patent expiries in 2026.
Wegovy’s prices are going down, but they are ‘wildly different’ — and confusing
How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average person to understand.
Novo Nordisk Stock Rises -- Alzheimer's Program Hints at Potential Gains
Novo Nordisk Stock Rises -- Alzheimer's Program Hints at Potential Gains
Novo Nordisk Leans on India After Trial Miss
Novo Nordisk Leans on India After Trial Miss
Novo Nordisk Leans on India After Trial Miss(edit)
Novo Nordisk Leans on India After Trial Miss(edit)
Novo Nordisk (NVO) Eyes Indian Market with Ozempic Launch
Novo Nordisk (NVO) Eyes Indian Market with Ozempic Launch
Novo Nordisk pushes ahead on Alzheimer’s efforts; said to plan December Ozempic rollout in India
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wedne...
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wedne...
Novo Nordisk gears up for December Ozempic launch in India, sources say
Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, as it seeks to strengthen its foothold in the world's ...
Medicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock?
The government has just negotiated a significant price reduction for the diabetes and weight-loss treatment. The stock jumped following this news, signaling that it's not as bad as it seems at first g...
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday,...
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
SAN DIEGO Dec 2 (Reuters) - Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top compa...
Here's Why Novo Nordisk Just Paid $2.1 Billion For Zaltenibart
Novo Nordisk to test next-gen obesity drug CagriSema in children
Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and adolescents, according to a U.S. registry of clinical trials.
Novo Nordisk to test next-gen obesity drug CagriSema in children
Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and adolescents, according to a U.S. registry of clinical trials.
Omeros (OMER) Secures $2.1B Deal with Novo Nordisk
Omeros (OMER) Secures $2.1B Deal with Novo Nordisk
Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.
Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know.
Semaglutide failed to demonstrate slowed Alzheimer's progression in EVOKE/EVOKE+ preliminary results, though some biomarkers improved. Stock plunged intraday, then partly recovered; shares are down ~4...
Notable healthcare headlines for the week: Sanofi, Eli Lilly, and Novo Nordisk in focus
Get the latest healthcare stock updates, key drug price negotiations, and policy changes impacting the S&P 500.